The CheckMate-143 study [4], a large-scale phase 3 study conducted in patients with recurrent GBM, compared Nivolumab, a PD-1 immune checkpoint inhibitor, and Bevacizumab, a control drug, but failed to demonstrate an effect on OS. The gene discussed is PDCD1; the disease is glioblastoma.